Intercept Pharmaceuticals (ICPT) Appoints Rachel Mcminn, Ph.D. As Chief Strategy Officer
4/30/2014 3:53:09 PM
NEW YORK, April 30, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver and intestinal diseases, today announced the appointment of Rachel McMinn, Ph.D. to the newly created position of Chief Strategy Officer.
Help employers find you! Check out all the jobs and post your resume.
comments powered by